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ABSTRACT 
Resembling most other techniques for medical imaging, ultrasound (US) changed radically that have 
ameliorate its spatial and temporal resolution, provided three-dimensional data, and permitted evaluation of dynamic 
physiologic processes similar to blood flow or tissue motion. The possibility of targeting US conflict agents to 
disease-related markers and for non-invasively evaluating the molecular profile of disease in animal models was 
strongly established. The technique is now being applied as a high-throughput research tool that can define 
pathophysiological processes in both the spatial and temporal domains. Early steps are presently under achievement 
in the direction of the advance of targeted agents appropriate for clinical use of this useful method. 
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1. INTRODUCTION 
The past decades have seen momentous developments in noninvasive medical imaging. Similar to most of 
systems for medical imaging, ultrasound (US) has undergone radical changes that have enhanced its spatial and 
temporal resolution, provided three-dimensional data, and permitted evaluation of dynamic physiologic processes 
for example: blood flow or tissue motion. This method is extensively used cross-sectional imaging modality 
worldwide. Important recent developments include MB contrast agents, quantitative approaches and new signal 
processing and display methods. Ultrasound is the sound at a frequency higher than 20 kHz, and may be crashed by 
the frequencies used. Clinical diagnostic ultrasound scanners use frequencies from 1 MHz to 20 MHz. One current 
advance has been the capacity to use molecular imaging (MI) to measure tissue phenotype, enzymatic movement or 
gene expression.  Even though methods for MI have been advanced for in effect every arrangement of medical 
imaging, there are substantial differences that inspiration the optimal of imaging method in both the research and 
clinical settings.  E.g., alterations in the recognition technique (e.g. US, gamma radioactivity indicator, magnetic 
resonance, visual light, etc.)  Inspiration spatial determination, sensitivity and practicality for use.  Alternatively, 
changes in the imaging probe effect virtual toxicity, biodistribution, sensitivity, specificity, and temporal resolution. 
High sensitivity, availability, rapid execution of imaging protocols, and the comparatively low rate are features of 
targeted MI with US that make this technique attractive particularly for screening large patient groups for a potential 
disease. US contrast agents have been in clinical use for years for applications.  For example blood pool 
improvement, characterization of liver scratches or perfusion imaging. These contrast agents are usually in the form 
of small acoustically active particles reaching from several hundred nanometers to a few micrometers in width. For 
clinical imaging, all contrast agents in current use are top secret as microbubbles (MBs) having a mean diameter of 
>1 mm. The principle behind using MBs such as US contrast agents is created on their compressibility. Gas-
containing MBs are numerous tips of magnitude more compressible than water or tissue, and are smaller than the 
wavelength of the applied US field in the diagnostic frequency range. Currently, US imaging generally plays a minor 
role in MI. Most of the clinical actions are attentive on PET and SPECT, and most of preclinical research is extended 
to the areas of optical imaging and MRI. However, with proper contrast agents designed for MI, US can play an 
essential role both in research and clinical applications. Historically, US contrast imaging was recommended for 
visualization of blood flow patterns. 
Basic mechanism of contrast agent in US: Early-generation US contrast agents included air bubbles equipped by 
fast mixing air with aqueous saline, albumin or X-ray difference media instantaneously (seconds) before 
intravascular administration. Air bubbles were echogenic but would rapidly dissolve in the blood; bubbles would not 
pass through the pulmonary circulation, hence monitoring blood flow subsequent intravenous management had not 
been feasible with those contrast particles. Other sometimes exotic, MB preparation approaches were investigated, 
such as intravenous administration of H2O2 to generate oxygen bubbles in vivo, but they did not gain widespread 
use. Next, so-called first-generation contrast supplies were much more steady and circulated longer than uncoated 
air bubbles because they were stabilized with a surfactant or a protein shell. They were able to trans pulmonary 
passage, so blood flow characterization after intravenous administration became possible, though circulation time of 
air-filled bubbles was generally quite short and these contrast agents did not gain much recognition in clinical use.  
Important clinical use of MBs for blood pool improvement became likely less than a decade ago, with the agreement 
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of second-generation contrast agents, which contained water- unsolvable fluorinated gases. These resources stayed 
in the bloodstream for minutes, not seconds, so, viable in vivo imaging studies have been performed. Particle size 
constraints apply to the design and applicability of MI with US contrast agents to attain successful imaging. In most 
cases, these resources are gas-filled MBs with the size of numerous microns. These subdivisions, with a picogram 
mass, are noticed by US very well, to the level of imaging separate particles in the adjourned public and even after 
binding to the target. Submicron gas bubbles keep much worse strength and circulation time; they are not as 
echogenic as larger bubbles. Therefore, favored contrast particle size is 2-4 um (larger MBs may lodge in the 
capillaries, e.g., in the lungs). It means that successful MI with present generation of MB contrast agents is thinkable 
only for intravascular markers, and US contrast detection of a precise cellular marker is not possible if that marker 
is not visible to the bloodstream and is located at the interstitial space or inside the target cell.  
Role of MB in MI: 15 years ago, dozens of papers describing MI with US contrast have appeared, presenting 
targeting to a variety of the disease marker molecules. General design of the particle has not changed suggestively 
since its first presentation. Targeting ligand is involved to the MB shell-forming substantial, then MBs are produced 
from inexplicable gas during high-shear mixing, e.g., with a probe-type sonicator. During the preparation procedure, 
MBs are instantaneously roofed with the shell. After removal of excess ligand by centrifugal flotation, MB targeting 
is either tested in vitro or injected intravenously in the experimental animals with the appropriate disease models. 
Most successful and popular targeted MB shell design is based on a lipid monolayer shell decorated with a grafted 
brush of the water-soluble polyethylene glycol. The depth of the lipid monolayer is ~2 nm. This tinny shell does not 
delay significantly with MB increase and reduction in the US field, providing good contrast echogenicity without 
the need to destroy the particles by blowing up the shell with great-power US. This shell does not attend as a 
significant barrier for gas diffusion in and out of the bubble. PEG chains extend from the MB surface into the 
surrounding aqueous environment by ~10-30 nm, which is not very important when compared with a 2-3 um particle 
diameter. Targeting ligand is usually attached to the exterior of the PEG brush in the same extended “fishing line” 
manner as it was earlier proposed for liposomes. This ligand coupling technique enables ligand-receptor interface 
and improves microparticle targeting in a flow-through scenario. 
Peptides/mimetics, carbohydrates, glycosulfopeptides, small and large proteins (such as antibodies) were 
successfully tested as ligands for MI using US. Most of tests like this, required biotinylated ligand which would 
assign to the bubble via a streptavidin spacer; many biotinylated ligands are available commercially or can be 
equipped easily. The advantage of biotin-streptavidin ligand linking method is in its simplicity; bubbles can be easily 
centrifuged to remove excess of free ligand. This approach is particularly useful if the ligand is a large protein that 
could become denatured and inactivated during MB preparation by sonication as labelled in the previous paragraph. 
However, there is a very important disadvantage. Streptavidin, as an uncommon protein, will not be agreed for 
clinical application in human setting. Therefore, chemical coupling amongst ligand and shell has to take place, either 
before (as described above) or after bubble preparation. The choice of ligands for MB targeting may be determined 
not just by the specificity and affinity of ligand-receptor interaction for the respective molecular markers 
(thermodynamics), but also by how fast the ligand-receptor interaction takes place (kinetics). Antibodies are usually 
selected via ELISA, by the value of equilibrium affinity, often described as equilibrium dissociation constant; 
however, the act of interaction of ligand-MB with the receptor on the vessel wall is a rather time constrained event, 
and if the kinetics of friendship between the ligand and receptor is slow, the MB would be transported away from 
the target area and would not assign to the intended target. However, successful particle targeting is possible via a 
mixture of speedy association between the ligand and receptor, and cooperative multipoint interaction between great 
number of ligand and receptor molecules. Placing over a million small ligand molecules per single MB is feasible. 
Only ~105 (or less) antibody molecules committed per MBs is typically reported. Using full IgG molecule for 
immobilization on the MB surface may not be the best strategy as compared with the use of smaller ligands: larger 
molecules carry much more than just the target binding sequence.  
Fc fragment of the antibody may be quite immunogenic, so the use of humanized (or fully human) antibodies 
is required. Furthermore, Fc receptors on phagocytic cells (e.g., in the liver) may alter mb biodistribution in an 
undesirable way. Overall, the use of smaller molecules as ligands for MI using US should be preferred. There are 
numerous useful intravascular molecular targets that mark disease tissue location; most of them are affiliated, directly 
or indirectly, with endothelial cells, and constitute markers of inflammation or angiogenesis. Imaging procedure is 
pretty straightforward, but somewhat different when compared with other MI modalities. Targeted MB construct 
aqueous dispersion (or control non-targeted preparation) is injected intravenously as a bolus, and low-power contrast 
US imaging of the region of interest is performed immediately. Contrast inflow imaging provides real-time 
information of the blood flow patterns in the tissue of interest, and may be useful for immediate understanding of the 
target tissue physiology.  Numerous minutes later, imaging of MBs that have knotted in the tissue can be performed. 
By that time, repeated circulation of the injected MBs through the body vasculature results in the selective binding 
of a fraction of the injected bubbles to the target, e.g., disease tissue. The majority of contrast agent is not likely to 
ISSN: 0974-2115 
www.jchps.com                                                                    Journal of Chemical and Pharmaceutical Sciences 
October - December 2016 2830 JCPS Volume 9 Issue 4 
adhere to the molecular marker of disease and is recirculating with the blood flow. MB shell is too thin to be a 
respectable barrier for air diffusion into the bubble and fluorocarbon diffusion out of the bubble. As MB contrast 
passes through the lungs, gas exchange with the surrounding medium takes place; most of the fluorocarbon gas is 
swapped out of the bubbles and exhaled within minutes of intravenous management. Residual air in the bubbles does 
not support good stability in vivo, it diffuses out and shell collapses, making the particle non-echogenic.  
Targeted bubbles, adhered e.g., to tumor vasculature, are not uncovered to fast flow convection conditions 
that support speedy gas exchange during circulation, so we can hypothesize that loss of gas from targeted bubbles 
would be slower. This method can contribute to the improvement of signalto- noise (e.g., target-to-blood) localization 
ratio. So at 5-15 minutes after MB administration, more of the circulating bubbles have cleared from the bloodstream, 
and imaging of adhered bubble can be achieved. Modern contrast modes (such as Contrast Pulse Sequencing or Pulse 
Inversion Amplitude Modulation) implemented on many US imaging systems allow to suppress the signal from the 
tissue itself, and observe MB with excellent detection sensitivity in real time at low power without contrast 
destruction (US Mechanical Index <0.2). After observing the targeted bubble in the particular imaging plane(s), US 
power can be increased, and adhered bubbles destroyed.  Decrease of the acoustic backscatter signal after destructive 
pulse can serve as an additional proof of MB targeting; within seconds after reduction of Mechanical Index, we can 
observe residual circulating bubbles still present in the bloodstream.   
DISCUSSION  
Nearly all of the MI using US studies defined in the literature so far has been performed in rodent animal 
models. There is an exception––a clinically approved agent that is routinely used for Kupffer cell targeting, Sonazoid 
(perflubutane MBs). It is approved for targeted US contrast in the liver radiology setting in Japan. It is likely that 
several hundred thousand patients have received this contrast agent since its approval. Sonazoid increase in normal 
liver parenchyma is achieved via phosphatidylserine targeting: Sonazoid MB consists of phosphatidylserine shell 
and perfluorobutane gas. As phosphatidylserine is the natural marker of apoptosis, its presence on the outer surface 
of a particle or a cell makes that surface an immediate target for phagocytic uptake. In the normal liver tissue but not 
in the lesion foci, Kupffer cells are present and can capture circulating MBs and allow better disease characterization 
by “negative” target enhancement, as compared with unenhanced US or dynamic CT. This “late-phase” US imaging 
is achieved to detect bubbles that have targeted to the normal liver tissue of interest following the clearance of 
circulating bubbles from the bloodstream, several minutes after bolus intravenous administration. As 
phosphatidylserine-targeted MBs are taken up by any phagocytic cells, they may be applied not only for liver 
radiology, but also for imaging of adherent neutrophils in the acute inflammation or ischemia/reperfusion injury 
scenarios.  
Generally, two strategies are generally employed for the targeting of MBs. The first involves modifying the 
constituents of the MB shell to facilitate their addition to cells encountered in disease areas, such as leucocytes. One 
example of this tactic is the incorporation of the negatively charged phospholipid phospatidylserine into the shell, 
which promotes activation and adhesion of complement to the MB shell and thus promotes MB attachment to 
activated leukocytes. Similarly, MBs with an albumin shell can attach to leukocytes through cell-surface receptors 
that bind albumin such as integrins. The second general targeting strategy consists of attaching disease-specific 
ligands, such as monoclonal antibodies, glycoproteins, carbohydrates, peptides or peptidomimetics to the MB shell. 
The ligands are conjugated either directly to the shell or involved to a polyethyleneglycol spacingmoiety that schemes 
the ligand away from the shell surface. Both covalent binding with maleimide or biotin– avidin links can be employed 
to attach the ligands to the MB shell. In general, several thousand binding molecules per square micron shell surface 
area can be conjugated. For successful targeting of a disease-related molecule, several factors have to be considered. 
The targeted molecule should be sufficiently particular for the disease course and should not be expressed 
constitutively in significant amounts.  
Attachment of MBs happens in the face of vascular flow, and thus factors like shear rate in the tissue of 
interest, ligand density on the MBs, bond affinity of the ligand (on- and off-rates), and target molecule density have 
to be considered. Up currently, the principle of targeting acoustically active particles for imaging disease has been 
established. A wide multiplicity of contrast agents and probes are currently in routine use in experimental setups. 
Unlike other MI techniques, particularly radionuclide based methods; MI with US is cheap, widely available, and 
easy to perform and has a good spatial and temporal resolution. It is a quantitative technique with high sensitivity 
and good signal-to-noise ratio. Despite of these advantages, further steps have to be made to facilitate its clinical 
application: optimization of MB adhesion to target structures is needed to further improve signal to noise ration of 
the technique. More disease specific targets will widen its clinical spectrum of applications. Imaging techniques 
could be improved by using new detection algorithms, considering the specific changes in acoustic assets of MBs 
when binding to a target. Although ultrasonic molecular imaging has made important growth over the last decade, 
this technology still faces several challenges before it can rise to its full diagnostic potential. It is the ideal goal of 
this technology to determine if a molecular target is present and, if so, to what degree. This involves that the contrast 
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agents explicitly adhere to their molecular target and bind in quantities great enough to overwhelm the signal 
contributions from nonspecific retention. Additionally, the ultrasound system should have sufficient sensitivity to 
detect the targeted agents present at the site of pathology and be able to measure the pathology in its entirety. In this 
review, we hypothesize that numerous limitations have slowed the development of ultrasonic molecular imaging; 
however, current advances in contrast agent development, ultrasound technology, and detection strategies 
demonstrate the probable to substantially improve the capabilities and utility of ultrasonic molecular imaging. We 
review these challenges and current advances in the following sections. 
2. CONCLUSION  
Targeted contrast-enhanced US is an emerging imaging. Strategy that syndicates US technology with novel 
molecularly targeted US. Contrast agents for assessing biological processes at the molecular level. US contrast agents 
are nano or micro-sized particles that are targeted to particular molecular markers by adding high-affinity binding 
ligands on to the surface of the particles. MI with US contrast agents represents a rapidly developing area of research. 
A combination of equipment portability, low cost and excellent contrast detection sensitivity by US imaging, in 
concert with the ability to detect molecular markers of disease in real time, will very likely lead to the development 
of MI contrast agents for widespread clinical application for diagnostic imaging and image-guided therapy. In 
conclusion, the possibility of directing US contrast causes to disease-related markers and for non-invasively 
evaluating the molecular profile of disease in animal models has been resolutely established. The technique is now 
being applied as a high-throughput research tool that can define pathophysiological processes in both the spatial and 
temporal domains.  Early steps are presently being made in the direction of the development of embattled agents 
appropriate for clinical application of this useful method. Following intravenous administration, these targeted US 
contrast agents accumulate at tissue sites overexpressing specific molecular markers, thereby enhancing the US 
imaging signal. High spatial and temporal resolution, real time imaging, non-invasiveness, relatively low costs, lack 
of ionizing irradiation and wide availability of US systems are advantages compared to other MI modalities. 
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